Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024.

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024.

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 –

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 –